全文获取类型
收费全文 | 55篇 |
免费 | 6篇 |
国内免费 | 5篇 |
专业分类
化学工业 | 13篇 |
金属工艺 | 4篇 |
轻工业 | 7篇 |
无线电 | 1篇 |
一般工业技术 | 3篇 |
冶金工业 | 36篇 |
自动化技术 | 2篇 |
出版年
2023年 | 3篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 1篇 |
2014年 | 4篇 |
2013年 | 1篇 |
2012年 | 1篇 |
2010年 | 3篇 |
2009年 | 3篇 |
2008年 | 3篇 |
2007年 | 6篇 |
2006年 | 8篇 |
2005年 | 4篇 |
2004年 | 3篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2001年 | 2篇 |
1985年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有66条查询结果,搜索用时 15 毫秒
1.
2.
Federica Prono Katerina Bernardi Raffaele Ferri Oliviero Bruni 《International journal of molecular sciences》2022,23(3)
This review investigates the association between vitamin D and sleep disorders. Vitamin D is an essential nutrient known to play an important role in the growth and bone health of the human body, but it also appears to play a role in sleep. The goal of our review is to examine the association between vitamin D and sleep disorders in children and adolescents. We summarize the evidence about the role and the mechanism of action of vitamin D in children and adolescents with sleep disorders such as insomnia, obstructive sleep apnea (OSA), restless legs syndrome (RLS), and other sleep disorders. Systematic electronic database searches were conducted using Pubmed and Cochrane Library. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was followed. The studies that met the established inclusion criteria were analyzed and compared. Results suggest a strict relationship between vitamin D deficiency in children and sleep disorders. There is evidence that vitamin D is implicated in the different neurochemical mechanisms involved in sleep regulation and mainly in the serotonergic and dopaminergic pathways. This might be responsible for the association of vitamin D deficiency and restless sleep, sleep hyperhidrosis, OSA, and RLS. 相似文献
3.
Dr. Christine Brotschi Dr. Martin H. Bolli Dr. John Gatfield Dr. Bibia Heidmann Dr. Francois Jenck Dr. Catherine Roch Dr. Thierry Sifferlen Dr. Alexander Treiber Dr. Jodi T. Williams Dr. Christoph Boss 《ChemMedChem》2020,15(5):430-448
The orexin system is responsible for regulating the sleep-wake cycle. Suvorexant, a dual orexin receptor antagonist (DORA) is approved by the FDA for the treatment of insomnia disorders. Herein, we report the optimization efforts toward a DORA, where our starting point was (5-methoxy-4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}methanone ( 6 ), a compound which emerged from our in-house research program. Compound 6 was shown to be a potent, brain-penetrating DORA with in vivo efficacy similar to suvorexant in rats. However, shortcomings from low metabolic stability, high plasma protein binding (PPB), low brain free fraction (fu brain), and low aqueous solubility, were identified and hence, compound 6 was not an ideal candidate for further development. Our optimization efforts addressing the above-mentioned shortcomings resulted in the identification of (4-chloro-2-[1,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}l-methanone ( 42 ), a DORA with improved in vivo efficacy compared to 6 . 相似文献
4.
Reviews the book, L'insomnie: Traitement comportemental by Robert Ladouceur and Yves Gros-Louis (1984). The work offers a prospect broader than the medical vision which traditionally dominates the treatment of insomnia. More specifically, the work is articulated around two chapters. The first locates the relative source data of insomnia, and provides the criteria for a precise diagnosis, establishing a clear distinction between primary insomnia and secondary insomnia, and methods generally utilized to measure sleep. As for the second chapter, it is centered on the behavioral methods of treatment of insomnia. According to the authors, any treatment must be preceded by factual information on insomnia, to facilitate the application of the chosen method. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献
5.
Bélanger Lynda; Morin Charles M.; Bastien Céyne; Ladouceur Robert 《Canadian Metallurgical Quarterly》2005,24(3):281
Better understanding of compliance with BZD taper is warranted. Compliance with a taper program and perceived self-efficacy (SE) in being able to comply with hypnotic reduction goals was monitored weekly in 52 older adults (mean age: 63.0 years) with chronic insomnia (average duration: 21.9 years) who underwent a 10-week physician-supervised medication tapering. One group received cognitive- behavior therapy for insomnia during discontinuation, whereas the other did not. Compliant patients showed higher SE ratings at Weeks 6, 8, 9, and 10. Medication-free patients at the end of the treatment also reported higher mean SE ratings at those 4 weeks. Differences remained significant when withdrawal symptoms and sleep efficiency were controlled for. These results have important clinical implications because SE may indicate key time points when patients are experiencing more difficulty during discontinuation. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献
6.
Rybarczyk Bruce; Lopez Martita; Benson Rodney; Alsten Christopher; Stepanski Edward 《Canadian Metallurgical Quarterly》2002,17(2):288
Older adults with comorbid insomnia and medical illness have been excluded from behavioral treatment research, but recent evidence suggested that such treatments would be effective with this population. In this study, 38 older adults with comorbid insomnia were randomized to 1 of 3 conditions: classroom cognitive-behavioral treatment (CBT), home-based audio relaxation treatment (HART), or delayed-treatment control. Compared to the control group, the CBT group had significant changes in 5 of 7 self-report measures of sleep at the 4-month follow-up. The HART group obtained significant outcomes on 3 of 7 measures. Wrist actigraphy measures and secondary-outcome measures did not yield significant findings for either treatment. Clinically significant changes at follow-up were obtained for 54% of patients in CBT, 35% in HART, and 6% in the control group when treatment dropouts were included. Although not as effective as in-person CBT, home interventions may have utility as a first-line, low-cost treatment. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献
7.
Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia 下载免费PDF全文
Dr. Anthony J. Roecker Swati P. Mercer John D. Schreier Dr. Christopher D. Cox Dr. Mark E. Fraley Justin T. Steen Wei Lemaire Joseph G. Bruno C. Meacham Harrell Susan L. Garson Dr. Anthony L. Gotter Steven V. Fox Joanne Stevens Dr. Pamela L. Tannenbaum Dr. Thomayant Prueksaritanont Dr. Tamara D. Cabalu Dr. Donghui Cui Joyce Stellabott Dr. George D. Hartman Dr. Steven D. Young Dr. Christopher J. Winrow Dr. John J. Renger Dr. Paul J. Coleman 《ChemMedChem》2014,9(2):311-322
The field of small‐molecule orexin antagonist research has evolved rapidly in the last 15 years from the discovery of the orexin peptides to clinical proof‐of‐concept for the treatment of insomnia. Clinical programs have focused on the development of antagonists that reversibly block the action of endogenous peptides at both the orexin 1 and orexin 2 receptors (OX1R and OX2R), termed dual orexin receptor antagonists (DORAs), affording late‐stage development candidates including Merck’s suvorexant (new drug application filed 2012). Full characterization of the pharmacology associated with antagonism of either OX1R or OX2R alone has been hampered by the dearth of suitable subtype‐selective, orally bioavailable ligands. Herein, we report the development of a selective orexin 2 antagonist (2‐SORA) series to afford a potent, orally bioavailable 2‐SORA ligand. Several challenging medicinal chemistry issues were identified and overcome during the development of these 2,5‐disubstituted nicotinamides, including reversible CYP inhibition, physiochemical properties, P‐glycoprotein efflux and bioactivation. This article highlights structural modifications the team utilized to drive compound design, as well as in vivo characterization of our 2‐SORA clinical candidate, 5′′‐chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064), in mouse, rat, dog, and rhesus sleep models. 相似文献
8.
Christian Veauthier Gunnar Gaede Helena Radbruch Klaus-Dieter Wernecke Friedemann Paul 《International journal of molecular sciences》2015,16(7):16514-16528
Quality of Life (QoL) is decreased in multiple sclerosis (MS), but studies about the impact of sleep disorders (SD) on health-related quality of Life (HRQoL) are lacking. From our original cohort, a cross-sectional polysomnographic (PSG) study in consecutive MS patients, we retrospectively analysed the previously unpublished data of the Nottingham Health Profile (NHP). Those MS patients suffering from sleep disorders (n = 49) showed significantly lower HRQoL compared to MS patients without sleep disorders (n = 17). Subsequently, we classified the patients into four subgroups: insomnia (n = 17), restless-legs syndrome, periodic limb movement disorder and SD due to leg pain (n = 24), obstructive sleep apnea (n = 8) and patients without sleep disorder (n = 17). OSA and insomnia patients showed significantly higher NHP values and decreased HRQoL not only for the sleep subscale but also for the “energy” and “emotional” area of the NHP. In addition, OSA patients also showed increased NHP values in the “physical abilities” area. Interestingly, we did not find a correlation between the objective PSG parameters and the subjective sleep items of the NHP. However, this study demonstrates that sleep disorders can reduce HRQoL in MS patients and should be considered as an important confounder in all studies investigating HRQoL in MS. 相似文献
9.
Stepanski Edward; Rybarczyk Bruce; Lopez Martita; Stevens Suzanne 《Canadian Metallurgical Quarterly》2003,48(1):23
Recent research has led to significant progress in the assessment and treatment of sleep disturbance in older adults. Similar advances have been made with sleep disorders secondary to age-related chronic illness. The assessment and treatment of sleep disorders encompasses numerous behavioral aspects. Thus, rehabilitation psychologists are ideally positioned to help apply these new advances to the growing number of older adult patients in the rehabilitation setting. The authors provide an overview of age and disease-related sleep disorders. They provide details for implementation of behavioral treatments for geriatric insomnia that is comorbid with chronic illness. (PsycINFO Database Record (c) 2011 APA, all rights reserved) 相似文献
10.
Belleville Geneviève; Guay Catherine; Guay Bernard; Morin Charles M. 《Canadian Metallurgical Quarterly》2007,75(2):325
This study aimed to assess the efficacy of a minimal intervention focusing on hypnotic discontinuation and cognitive-behavioral treatment (CBT) for insomnia. Fifty-three adult chronic users of hypnotics were randomly assigned to an 8-week hypnotic taper program, used alone or combined with a self-help CBT. Weekly hypnotic use decreased in both conditions, from a nearly nightly use at baseline to less than once a week at posttreatment. Nightly dosage (in lorazepam equivalent) decreased from 1.67 mg to 0.12 mg. Participants who received CBT improved their sleep efficiency by 8%, whereas those who did not remained stable. Total wake time decreased by 52 min among CBT participants and increased by 13 min among those receiving the taper schedule alone. Total sleep time remained stable throughout withdrawal in both CBT and taper conditions. The present findings suggest that a systematic withdrawal schedule might be sufficient in helping chronic users stop their hypnotic medication. The addition of a self-help treatment focusing on insomnia, a readily available and cost-effective alternative to individual psychotherapy, produced greater sleep improvement. (PsycINFO Database Record (c) 2010 APA, all rights reserved) 相似文献